Salute e Benessere

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024–Immatics N.V.(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be...
Nasdaq GlobeNewswire
18/01/2024

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to…

Key Takeaways from the Non-Alcoholic Steatohepatitis Market Report Key Takeaways from the Non-Alcoholic Steatohepatitis Market Report Discover which therapies are expected to grab the major NASH market share @Non-Alcoholic Steatohepatitis Market Report Non-Alcoholic Steatohepatitis Overview Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that has gained prominence due to its increasing prevalence worldwide. Unlike simple fatty liver, NASH is characterized...
PR Newswire
17/01/2024

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period…

Key Takeaways from the Beta-thalassemia Market Report Key Takeaways from the Beta-thalassemia Market Report Discover which therapies are expected to grab the major beta-thalassemia market share @Beta-thalassemia Market Report Beta-thalassemia Overview Beta-thalassemia (β-thalassemia) is a blood disorder marked by a diminished production of the beta subunit of hemoglobin, leading to microcytic hypochromic anemia, an atypical blood smear with nucleated red blood cells, and...
PR Newswire
17/01/2024

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,036,828 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
17/01/2024

Taro Announces Merger Agreement with Sun Pharma

Dilip Shanghvi, Managing Director of Sun Pharma, said, "Over the years, with Sun Pharma's strategic interventions, Taro has remained a key player in the generic dermatology market in a challenging environment. Post completion of the merger, the combined entity will firmly move forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals." Dilip Shanghvi, Managing Director of Sun Pharma, said, "Over the years, with Sun…
PR Newswire
17/01/2024

Nyxoah Announces 2024 Strategic Priorities

Nyxoah Announces 2024 Strategic PrioritiesMont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024. 2024 Strategic Priorities Complete patient...
Nasdaq GlobeNewswire
17/01/2024

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024–Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size...
Nasdaq GlobeNewswire
17/01/2024

5G in Healthcare Market to Zoom to US$1.8 Trillion by 2034, Driven by Robotics…

Request Exclusive Sample Report: 5G Technology in Healthcare Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-12783 Request Exclusive Sample Report: 5G Technology in Healthcare Industry Strategic Insights,https://www.futuremarketinsights.com/reports/sample/rep-gb-12783 Healthcare is integrating technology into its workings at an increasing rate. One such technology making its way intohealthcare is 5G. With a need for better communication in...
PR Newswire
17/01/2024

Huge Demand for Pet Care Globally, Annual Revenue to Reach $400 Billion by 2028…

Browse in-depth TOC on "Pet Care Market" 298 – Pages 133 - Tables 116 - Figures Pet Care Market Report Scope The major contributor to the growth of the pet care market is the pet food industry, as it is an essential part of the regular life of a pet. Pets require a wide range of nutrients and proteins to ensure that they can perform their daily activities. The industrial pet food market is more dominant in the European and North American regions...
PR Newswire
17/01/2024

Octapharma to present clinical and scientific data that advances our…

WIL-31 is the largest prospective prophylaxis study in VWD with an on-demand run-in study as an intra-individual patient comparator. The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites. The results provide compelling evidence for the use of regular prophylaxis in people with VWD. WIL-31 is the largest prospective prophylaxis study in VWD with an on-demand run-in study as an...
PR Newswire
17/01/2024

Global Metagenomic Sequencing Market to Reach US$ 4.39 Billion by 2030, Rising…

Furthermore, the increasing demand for accurate and rapid diagnostic solutions has also contributed to the market growth. Metagenomic sequencing offers a comprehensive genetic analysis of microbial communities, enabling healthcare professionals to identify and track potential pathogens. This enables better disease control and prevention strategies, leading to improved patient outcomes. Furthermore, the increasing demand for accurate and rapid diagnostic solutions has also contributed to the…
PR Newswire
17/01/2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM – January 17, 2024 – 7:00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on January 16, 2024, from Atlas Special Opportunities, LLC indicating that as of January 9, 2024, it held 356,983,730 shares of the then outstanding...
Nasdaq GlobeNewswire
17/01/2024

The Global Surge in Continuing Medical Education Demand Predicts Revenue Soaring…

Browse in-depth TOC on the "Continuing Medical Education Market" Browse in-depth TOC on the "Continuing Medical Education Market" 376 – Pages 205 - Tables 155 - Figures Continuing Medical Education Market Report Scope In recent years, several changes and developments have changed the overall Continuing medical education market landscape at the global level. Worldwide, the COVID-19 pandemic has broadly affected the healthcare system. The huge impact of...
PR Newswire
17/01/2024

VIRBAC: Annual revenue growth of +4.9% thanks to record fourth-quarter activity…

KEY FIGURES Annual Revenue 2023 €1,246.9 millionGrowth at constant exchange ratesand scope 1 +4.9%of which companion animals +3.5%farm animals +6.7%Growth at constantexchange rates +4.9% Overallchange +2.5% 1 growth at constant exchange rates and scope corresponds to organic growth of revenue, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator...
Nasdaq GlobeNewswire
17/01/2024

Sleep Apnea Devices Market Size & Share to Surpass USD 20 Billion by 2035 |…

The global sleep apnea devices market is growing rapidly; it is estimated to be worth USD 13.5 billion in 2023 and is anticipated to reach over USD 20 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 4.61% during the forecast period from 2023 to 2035. The globalsleep apnea devices market is growing rapidly; it is estimated to be worthUSD 13.5 billion in 2023 and is anticipated to reach overUSD 20 billionby 2035. It is expected to grow at a...
PR Newswire
17/01/2024

Cell Line Development Market Size to Surpass USD 4.5 Billion by 2035 | Roots…

Global Cell Line Development Market Overview Global Cell Line Development Market Overview The global cell line development market is growing rapidly; it is estimated to be worth USD 1.01 billion in 2023 and is expected to reach USD 4.5 billion by 2035. It is anticipated to grow at a higherCAGR of 13.2%during the forecast period from 2023 to 2035. Cell line development is the most crucial process in the biopharmaceutical industry; it involves in-vitro culturing of...
PR Newswire
17/01/2024

Consumer Genomics Market reach $4.38 billion by 2031 Globally, at a CAGR of…

An increasing adoption of inorganic growth strategies such as acquisition by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, in September 2021, Invitae Corp., a medical genetics company, announced the acquisition of Ciitizen, a consumer health technology company. This acquisition will expand the consumer genomics product portfolio of Invitae Corp. An increasing adoption of inorganic growth strategies such as acquisition by…
PR Newswire
17/01/2024

Advanced Wound Care Market Size to Exceed USD 20.21 Billion by 2035 | Roots…

Global Advanced Wound Care Market Overview Global Advanced Wound Care Market Overview The global advanced wound care market is growing exponentially; it is estimated to be worthUSD 11.06 billionin 2023 and is anticipated to reachUSD 20.21 billionby 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 5.15% during the forecast period from 2023 to 2035. Advanced wound care solutions refer to a class of products that helps expedite wound healing and prevent...
PR Newswire
17/01/2024

Postponement of the decision on the adoption of a sale plan (plan de cession)…

Postponement of the decision on the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings to January 31, 2024Paris, France, January 17, 2024 – 5:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial Court has postponed its decision on the...
Nasdaq GlobeNewswire
17/01/2024

Oral Proteins and Peptides Market Size to be Worth USD 8.4 Billion by 2032 |…

Global Oral Proteins and Peptides Market Overview Global Oral Proteins and Peptides Market Overview The global oral protein and peptide market is growing rapidly; it is estimated to be worthUSD 1.5 billionin 2023 and is anticipated to reachUSD 8.4 billion by 2032. It is expected to grow at a compounded annual growth rate (CAGR) of 20% during the forecast period from 2022 to 2032. Oral proteins are a special form of pharmaceutical composition that can be administered orally...
PR Newswire
17/01/2024

Exosome Research Market Worth $356 Million | MarketsandMarkets™

Browse in-depth TOC on "Exosome Research Market" Browse in-depth TOC on "Exosome Research Market" 217 - Tables 39 - Figures 238 - Pages Exosome Research Market Scope: The reagents & kits segment accounted for the largest share by product & service in the exosome research market in 2022. By products & services, the exosome research market has been categorized in reagents & kits, instruments, and services. The kits and reagents segment is further...
PR Newswire
17/01/2024

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 17 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital...
Nasdaq GlobeNewswire
17/01/2024

Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology…

Seno Medical's trendsetting approach lies in the ability of its advanced breast cancer diagnosis technology to address critical industry challenges, such as staff shortages and the high rate of unnecessary biopsies. Its Imagio® Breast Imaging System, which received Pre-Market Approval (PMA) from the US Food and Drug Administration (FDA) in 2021, seamlessly combines opto-acoustics and ultrasound to provide clinicians with real-time results. Seno Medical's solution is more effective and…
PR Newswire
17/01/2024

Shaping International Economics and Ethical Dialogues Through the Leadership of…

WCEF will continue to strive for its mission and legacy next year, encouraging collaborative spirit for economic advancement and innovative alliances for shared growth. WCEF will continue to strive for its mission and legacy next year, encouraging collaborative spirit for economic advancement and innovative alliances for shared growth. The World Anti-Corruption Conference 2023 (WACC) inJakarta, Indonesia, convened global leaders, experts, and practitioners at the Royal Kuningan Hotel...
PR Newswire
17/01/2024
Altri  Comunicati